Research
Cellular
All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.
Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.
StrongSupportsmedium confidence
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8–6 mg/wk), Tirzepatide (5 mg/wk, 10–15 mg/wk), and Semaglutide (0.7–1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo.
Why this rating
Based on a meta-analysis of five RCTs.
Source
Histological efficacy of anti‐diabetic agents in <scp>MASH</scp> and the mediating role of weight loss: A network meta‐analysis
Mainak Banerjee et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70187
Meta-analysisCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →